Want to see JANX full AI Analyst Report?
JANX Stock Chart & Stats
$15.82
-$2.71(-4.69%)
At close: 4:00 PM EST
$15.82
-$2.71(-4.69%)
Day’s Range― - ―
52-Week Range$12.12 - $35.34
Previous CloseN/A
Volume1.13M
Average Volume (3M)1.25M
Market Cap
$1.02B
Enterprise Value$832.67M
Total Cash (Recent Filing)$956.39M
Total Debt (Recent Filing)$21.57M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Aug 11, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding60,984,352
10 Day Avg. Volume1,855,365
30 Day Avg. Volume1,249,369
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)0.89
Price to Sales (P/S)85.51
P/FCF Ratio-10.27
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue38.53
Enterprise Value/Gross Profit-47.66
Enterprise Value/Ebitda-7.40
Forecast
1Y Price Target
$31.00Price Target Upside95.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.72
Revenue Forecast (FY)$32.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage Balance SheetVery low debt-to-equity (~0.02) gives Janux durable financial flexibility to fund clinical development and absorb operating losses without near-term solvency pressure. This buffer improves optionality for partnerships, licensing deals, or staged financings over the next 2–6 months.
Improving Revenue MomentumA 20.9% TTM revenue rebound signals improving top-line traction for a clinical-stage biotech, likely from collaborations or milestone recognitions. Sustained revenue growth can lengthen runway, validate progress on programs and enhance the firm's ability to fund R&D without immediate dilutive capital raises.
Stable Governance And Shareholder SupportStrong shareholder participation, board continuity and auditor ratification reflect stable governance and investor support. This reduces execution risk, facilitates orderly leadership transitions, and strengthens credibility with potential partners and financers when pursuing long‑term clinical and commercial strategies.
Bears Say
Persistent Deep LossesLarge negative EBIT/EBITDA and very negative net margins indicate operations are far from self-sustaining. Persistent losses erode equity (ROE about -12%) and require ongoing external funding, increasing execution risk if capital markets or partner deals slow over the next several months.
Weak Cash Generation / Rising BurnSignificant negative operating and free cash flow, with deterioration versus prior year, show burn is not yet stabilizing. Chronic cash outflows constrain program advancement absent financing or partner funding and raise the likelihood of dilutive capital raises or deal-dependent milestones.
No Commercial Products; Financing RelianceAs a clinical‑stage biotech without approved products, Janux must fund operations via equity raises and collaborations. This structural reliance creates funding and execution risk tied to capital markets and milestone timing, potentially delaying programs if external financing is constrained.
Janux Therapeutics Inc News
JANX FAQ
What was Janux Therapeutics, Inc.’s price range in the past 12 months?
Janux Therapeutics, Inc. lowest stock price was $12.12 and its highest was $35.34 in the past 12 months.
What is Janux Therapeutics, Inc.’s market cap?
Janux Therapeutics, Inc.’s market cap is $1.02B.
When is Janux Therapeutics, Inc.’s upcoming earnings report date?
Janux Therapeutics, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 31 days.
How were Janux Therapeutics, Inc.’s earnings last quarter?
Janux Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.551 by $0.161.
Is Janux Therapeutics, Inc. overvalued?
According to Wall Street analysts Janux Therapeutics, Inc.’s price is currently Undervalued.
Does Janux Therapeutics, Inc. pay dividends?
Janux Therapeutics, Inc. does not currently pay dividends.
What is Janux Therapeutics, Inc.’s EPS estimate?
Janux Therapeutics, Inc.’s EPS estimate is -0.25.
How many shares outstanding does Janux Therapeutics, Inc. have?
Janux Therapeutics, Inc. has 60,984,352 shares outstanding.
What happened to Janux Therapeutics, Inc.’s price movement after its last earnings report?
Janux Therapeutics, Inc. reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.551. Following the earnings report the stock price went down -2.51%.
Which hedge fund is a major shareholder of Janux Therapeutics, Inc.?
Currently, no hedge funds are holding shares in JANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Janux Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.00 (95.95% Upside)
$31.00 (95.95% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 289.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $85.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.28%
12-Months-Change
Fundamentals
Return on Equity
-11.85%
Trailing 12-Months
Asset Growth
-2.15%
Trailing 12-Months
Company Description
Janux Therapeutics, Inc.
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
JANX Stock 12 Month Forecast
Average Price Target
$31.00
▲(95.95% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Vera Therapeutics
―
Biohaven Ltd.
―
Ownership Overview
20.15% Insiders
13.19% Mutual Funds
0.26% Other Institutional Investors
53.98% Public Companies and
Individual Investors